GlassScriptPhysician profile
Madeline J Bebee
NPI 1134993991
$1,350.57
in general payments reported to CMS, 2019-2025
16 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $227 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $205.72 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.68 | 2025 | Caplyta |
| Gilead Sciences, INC. | $192.53 | 2024-2025 | Yeztugo, Biktarvy |
| Astrazeneca Pharmaceuticals LP | $133.46 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Emd Serono, INC. | $95.23 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $94.78 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $89.59 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $69.67 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $69.52 | 2025 | Pifeltro, Delstrigo |
| Novo Nordisk INC | $47.08 | 2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $42.48 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $26.21 | 2025 | Rhythmia Mapping System |
| Napo Pharmaceuticals INC | $24.83 | 2025 | Mytesi |
| Pfizer INC. | $21.54 | 2025 | |
| Amgen INC. | $19.64 | 2025 | Otezla, Repatha |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.61 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Bebee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.